Table 5.
Binary logistic regression analysis to identify the predictors of LVEF recovery in the patients with cancer therapy-related cardiomyopathy.
| Predictors of LVEF recovery | ||||||
|---|---|---|---|---|---|---|
| Univariate | Multivariate | |||||
| OR | CI 95% | p -value | OR | CI 95% | p -value | |
| Age (1 year) | 0.99 | 0.95–1.03 | 0.63 | 0.94 | 0.88–0.99 | 0.03 |
| Female sex | 1.39 | 0.38–5.08 | 0.62 | |||
| No smoking history | 0.93 | 0.18–4.98 | 0.94 | |||
| Arterial hypertension | 0.80 | 0.26–2.42 | 0.79 | |||
| Dyslipidemia | 0.72 | 0.20–2.64 | 0.62 | |||
| Diabetes | 0.66 | 0.11–3.86 | 0.64 | |||
| BMI (1 kg/m2) | 1.03 | 0.85–1.24 | 0.77 | |||
| Baseline LVEF (1%) | 1.07 | 0.97–1.17 | 0.20 | |||
| LVEF at the time of diagnosis of CTRCD (1%) | 1.10 | 1.03–1.2 | 0.002 | 1.13 | 1.03–1.25 | 0.008 |
| Trastuzumab treatment | 6.00 | 1.60–22.46 | 0.008 | 3.15 | 0.44–22.8 | 0.26 |
| Anthracyclines treatment | 0.83 | 0.26–2.61 | 0.75 | |||
| Thoracic radiotherapy | 2.1 | 0.75–6.03 | 0.16 | |||
| HF admission at CTRCD diagnosis | 0.35 | 0.10–1.28 | 0.11 | |||
| Cardiac specific treatment | 1.56 | 0.42–5.80 | 0.51 | |||
| Beta-blocker treatment | 0.80 | 0.28–2.29 | 0.68 | |||
| Carvedilol treatment | 4.58 | 1.02–20.69 | 0.048 | 1.78 | 0.27–11.6 | 0.55 |
| ACE-I treatment | 1.19 | 0.41–3.45 | 0.74 | |||
| ARB treatment | 0.91 | 0.22–3.78 | 0.89 | |||
| MRA treatment | 1.04 | 0.25–4.26 | 0.96 | |||
| Time from starting chemotherapy to dysfunction (1 month) | 0.99 | 0.98–1.00 | 0.035 | 0.99 | 0.98–1.00 | 0.023 |
ACE-I, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blockers; BMI, body mass index; CI, confidence interval; CTRCD, cancer therapy-related cardiac dysfunction; CV, cardiovascular; HF, heart failure; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; OR, odds ratio.
Cardiac-specific treatment meant to receive at least ACE-I/ARB after CTRCD diagnosis. Bold means statistically significant (p < 0.05).